2017

2017-12-01 サイト 管理者



16: Owada Y, Tamura T, Tanoi T, Ozawa Y, Shimizu Y, Hisakura K, Matsuzaka T, Shimano H, Nakano N, Sakashita S, Matsukawa T, Isoda H, Ohkohchi N.

Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features.

Pathol Int. in press, 2017.


15: Kobayashi M, Takeda K, Narita T, Nagai K, Okita N, Sudo Y, Miura Y, Tsumoto H, Nakagawa Y, Shimano H,
Higami Y.
Mitochondrial intermediate peptidase is a novel regulator of sirtuin-3 activation by caloric restriction.
FEBS Lett. in press, 2017.

14: Kodama S, Fujihara K, Ishiguro H, Horikawa C, Ohara N, Yachi Y, Tanaka S, Shimano H, Kato K, Hanyu O,
Sone H.
Quantitative Relationship Between Cumulative Risk Alleles Based on Genome-Wide Association Studies and
Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
J Epidemiol. in press, 2017.


13: Sawada Y, Izumida Y, Takeuchi Y, Aita Y, Wada N, Li E, Murayama Y, Piao X, Shikama A, Masuda Y, Nishi-Tatsumi M, Kubota M, Sekiya M, Matsuzaka T, Nakagawa Y, Sugano Y, Iwasaki H, Kobayashi K, Yatoh S, Suzuki H, Yagyu H, Kawakami Y, Kadowaki T, Shimano H, Yahagi N.

Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry.

Biochem Biophys Res Commun. 493(1):40-45, 2017.


12: Shimano H, Sato R.

SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology.

Nat Rev Endocrinol. 13(12):710-730, 2017.


11: Matsunaga S, Tanaka S, Fujihara K, Horikawa C, Iimuro S, Kitaoka M, Sato A, Nakamura J, Haneda M, Shimano H, Akanuma Y, Ohashi Y, Sone H.

Association between all-cause mortality and severity of depressive symptoms in patients with type 2 diabetes: Analysis from the Japan Diabetes Complications Study (JDCS).

J Psychosom Res. 99:34-39, 2017.

 

10: Muranaka H, Hayashi A, Minami K, Kitajima S, Kohno S, Nishimoto Y, Nagatani N, Suzuki M, Kulathunga LAN, Sasaki N, Okada N, Matsuzaka T, Shimano H, Tada H, Takahashi C.

A distinct function of the retinoblastoma protein in the control of lipid composition identified by lipidomic profiling.

Oncogenesis. 6(6):e350, 2017.

 

9: Chida T, Ito M, Nakashima K, Kanegae Y, Aoshima T, Takabayashi S, Kawata K, Nakagawa Y, Yamamoto M, Shimano H, Matsuura T, Kobayashi Y, Suda T, Suzuki T.

Critical role of CREBH-mediated induction of TGF-β2 by HCV infection in fibrogenic responses in hepatic stellate cells.

Hepatology. 66(5):1430-1443, 2017.


8: Zhao H, Matsuzaka T, Nakano Y, Motomura K, Tang N, Yokoo T, Okajima Y, Han SI, Takeuchi Y, Aita Y, Iwasaki H, Yatoh S, Suzuki H, Sekiya M, Yahagi N, Nakagawa Y, Sone H, Yamada N, Shimano H.

Elovl6 Deficiency Improves Glycemic Control in Diabetic db/db Mice by Expanding β-Cell Mass and Increasing Insulin Secretory Capacity.

Diabetes. 66(7):1833-1846, 2017.


7: Takanashi M, Taira Y, Okazaki S, Takase S, Kimura T, Li CC, Xu PF, Noda A, Sakata I, Kumagai H, Ikeda Y, Iizuka Y, Yahagi N, Shimano H, Osuga JI, Ishibashi S, Kadowaki T, Okazaki H.

Role of Hormone-sensitive Lipase in Leptin-Promoted Fat Loss and Glucose Lowering.

J Atheroscler Thromb. 24(11):1105-1116, 2017.

 

6: Takei K, Nakagawa Y, Wang Y, Han SI, Satoh A, Sekiya M, Matsuzaka T, Shimano H.

Effects of K-877, a novel selective PPARα modulator, on small intestine contribute to the amelioration of hyperlipidemia in low-density lipoprotein receptor knockout mice.

J Pharmacol Sci. 133(4):214-222, 2017.


5: Nishi-Tatsumi M, Yahagi N, Takeuchi Y, Toya N, Takarada A, Murayama Y, Aita Y, Sawada Y, Piao X, Oya Y, Shikama A, Masuda Y, Kubota M, Izumida Y, Matsuzaka T, Nakagawa Y, Sekiya M, Iizuka Y, Kawakami Y, Kadowaki T, Yamada N, Shimano H.

A key role of nuclear factor Y in the refeeding response of fatty acid synthase in adipocytes.

FEBS Lett. 591(7):965-978, 2017.


4: Fujihara K, Igarashi R, Matsunaga S, Matsubayashi Y, Yamada T, Yokoyama H, Tanaka S, Shimano H, Maegawa H, Yamazaki K, Kawai K, Sone H.

Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42).

Medicine (Baltimore). 96(7):e6122, 2017.

 

3: Takei K, Han SI, Murayama Y, Satoh A, Oikawa F, Ohno H, Osaki Y, Matsuzaka T, Sekiya M, Iwasaki H, Yatoh S, Yahagi N, Suzuki H, Yamada N, Nakagawa Y, Shimano H.

Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.

J Diabetes Investig. 8(4):446-452, 2017.

 

2: Kodama S, Fujihara K, Ishiguro H, Horikawa C, Ohara N, Yachi Y, Tanaka S, Shimano H, Kato K, Hanyu O, Sone H.

Unstable body weight and incident type 2 diabetes mellitus - A meta-analysis.

J Diabetes Investig. 8(4):501-509, 2017.

 

1: Oishi Y, Spann NJ, Link VM, Muse ED, Strid T, Edillor C, Kolar MJ, Matsuzaka T, Hayakawa S, Tao J, Kaikkonen MU, Carlin AF, Lam MT, Manabe I, Shimano H, Saghatelian A, Glass CK.

SREBP1 Contributes to Resolution of Pro-inflammatory TLR4 Signaling by Reprogramming Fatty Acid Metabolism.

Cell Metab. 25(2):412-427, 2017.